Earnings summaries and quarterly performance for ALNYLAM PHARMACEUTICALS.
Executive leadership at ALNYLAM PHARMACEUTICALS.
Yvonne Greenstreet
Detailed
Chief Executive Officer
CEO
JP
Jeffrey Poulton
Detailed
Executive Vice President, Chief Financial Officer
KF
Kevin Fitzgerald
Detailed
Executive Vice President, Chief Scientific Officer
PG
Pushkal Garg
Detailed
Executive Vice President, Chief Research and Development Officer
RH
Robert Hesslein
Detailed
Executive Vice President, Chief Legal Officer and Secretary
TT
Tolga Tanguler
Detailed
Executive Vice President, Chief Commercial Officer
Board of directors at ALNYLAM PHARMACEUTICALS.
AS
Amy Schulman
Detailed
Chair of the Board
CB
Carolyn Bertozzi
Detailed
Director
CR
Colleen Reitan
Detailed
Director
DP
David Pyott
Detailed
Director
DA
Dennis Ausiello
Detailed
Director
ES
Elliott Sigal
Detailed
Director
MH
Margaret Hamburg
Detailed
Director
MB
Michael Bonney
Detailed
Director
OB
Olivier Brandicourt
Detailed
Director
PK
Peter Kellogg
Detailed
Director
Research analysts who have asked questions during ALNYLAM PHARMACEUTICALS earnings calls.
JF
Jessica Fye
JPMorgan Chase & Co.
6 questions for ALNY
Also covers: ALKS, AMRN, ASND +23 more
RB
Ritu Baral
TD Cowen
6 questions for ALNY
Also covers: ACAD, ATAI, BOLD +11 more
TA
Tazeen Ahmad
Bank of America
6 questions for ALNY
Also covers: ACAD, APLS, ARGX +20 more
LI
Luca Issi
RBC Capital Markets
5 questions for ALNY
Also covers: ADVM, ALLO, AMGN +12 more
Gena Wang
Barclays
4 questions for ALNY
Also covers: BCRX, BLUE, BMRN +12 more
Paul Matteis
Stifel
4 questions for ALNY
Also covers: ABOS, ACAD, ALKS +11 more
Salveen Richter
Goldman Sachs
4 questions for ALNY
Also covers: ACAD, AGIO, ALLO +20 more
EM
Eliana Merle
UBS
3 questions for ALNY
Also covers: APLS, ARVN, ARWR +17 more
Gary Nachman
Raymond James
3 questions for ALNY
Also covers: ABBV, ACHV, ADMA +9 more
MR
Maury Raycroft
Jefferies
3 questions for ALNY
Also covers: ABEO, ARWR, BCRX +11 more
AJ
Adithya Jayaraman
Evercore
2 questions for ALNY
HW
Huidong Wang
Barclays
2 questions for ALNY
Also covers: BCRX, BEAM, BLUE +15 more
JP
Julian Pino
Jefferies
2 questions for ALNY
Also covers: ACAD, ALEC, BMRN +2 more
KB
Konstantinos Biliouris
BMO Capital Markets
2 questions for ALNY
Also covers: BEAM, BMRN, LEGN +3 more
Kostas Biliouris
BMO Capital Markets
2 questions for ALNY
Also covers: BMRN, LEGN, NTLA +2 more
MU
Michael Ulz
Morgan Stanley
2 questions for ALNY
Also covers: ARWR, FATE, GUTS +8 more
DL
David Lebowitz
Citigroup Inc.
1 question for ALNY
Also covers: ARWR, ASND, BPMC +11 more
EM
Ellie Merle
UBS Group AG
1 question for ALNY
Also covers: ALT, ARVN, ARWR +12 more
MF
Mani Foroohar
Leerink Partners
1 question for ALNY
Also covers: ADVM, ARWR, BBIO +9 more
MR
Maurice Raycroft
Jefferies Financial Group
1 question for ALNY
Also covers: ABEO, AFMD, ARWR +14 more
TV
Teresa Vitali
Scotiabank
1 question for ALNY
Also covers: GERN
TV
Theresa Vitelle
Scotiabank
1 question for ALNY
Tommie Reerink
Goldman Sachs
1 question for ALNY
Also covers: ATRA, BMRN, BPMC +2 more
Recent press releases and 8-K filings for ALNY.
Alnylam Announces $250 Million Manufacturing Facility Expansion
ALNY
New Projects/Investments
- Alnylam Pharmaceuticals (ALNY) plans a $250 million investment to expand its manufacturing facility in Norton, Massachusetts.
- This expansion will integrate the siRELIS™ enzymatic ligation platform, which is expected to substantially increase manufacturing capacity and significantly reduce production costs.
- The new capabilities are projected to become fully operational by late 2027.
- The U.S. Food and Drug Administration (FDA) has accepted the siRELIS™ platform into its Emerging Technology Program, which will accelerate global regulatory engagement.
Dec 17, 2025, 1:00 PM
Alnylam Announces Partial Repurchase of Convertible Senior Notes
ALNY
- Alnylam Pharmaceuticals, Inc. has entered into agreements to repurchase approximately $34.4 million aggregate principal amount of its 1.00% convertible senior notes due 2027.
- The total repurchase cost, including accrued and unpaid interest, is approximately $51.9 million.
- Following these transactions, approximately $362.8 million aggregate principal amount of the notes will remain outstanding.
Dec 11, 2025, 12:25 PM
Alnylam Provides Update on Amvuttra Launch, Pipeline, and Strategic Goals
ALNY
Product Launch
New Projects/Investments
Guidance Update
- Alnylam is on the cusp of delivering its P5x25 goals, which include achieving sustainable non-GAAP profitability, and plans to announce new objectives early next year.
- The Amvuttra cardiomyopathy launch has had a "terrific start," with patient volume demand doubling in the last quarter and broad utilization across first-line and second-line patients. The company expects continued growth in the TTR market, where only 20% of an estimated 150,000 US patients are currently diagnosed.
- Alnylam is advancing Nucresiran, its next-generation TTR program, with Phase 3 studies targeting market entry around 2028 for polyneuropathy and 2030 for cardiomyopathy, offering >95% TTR knockdown and a twice-a-year regimen.
- The company has initiated a Phase 1 study for its Huntington's disease program, which aims to knock down the full-length Huntington protein and exon one fragment.
Nov 19, 2025, 11:30 AM
Alnylam Discusses Strong Amvuttra Launch and Pipeline at Jefferies Conference
ALNY
Product Launch
Guidance Update
New Projects/Investments
- Alnylam, a leading RNAi company, is on the cusp of achieving its P5x25 goals, which include sustainable non-GAAP profitability, and will announce new objectives early next year.
- The launch of Amvuttra for cardiomyopathy has seen a "terrific start", with access to key healthcare systems achieved rapidly and patient volume demand doubling in the last quarter (Q3 2025), leading to increased guidance.
- The company anticipates continued growth in the TTR cardiomyopathy market, where only 20% of an estimated 300,000 global patients are currently diagnosed, and is advancing Nucresiran, a next-generation TTR therapy, with potential launches in 2028 (polyneuropathy) and 2030 (cardiomyopathy).
- Alnylam's clinical pipeline includes several potential blockbuster opportunities, such as zilebesiran for hypertension and a promising Phase 1 program for Huntington's disease, which is considered a key catalyst.
Nov 19, 2025, 11:30 AM
Alnylam Reports Strong Amvuttra Launch and Pipeline Progress
ALNY
Product Launch
New Projects/Investments
Guidance Update
- Alnylam reported a terrific start to the Amvuttra cardiomyopathy launch, with patient volume demand doubling in the last quarter (Q3 2025). Amvuttra is gaining traction as a first-line therapy and capturing a significant share of second-line opportunities.
- The company is advancing Nucresiran, its next-generation TTR program, targeting over 95% TTR knockdown with a twice-a-year regimen. Phase III studies are underway, with potential market entry in 2028 for polyneuropathy and 2030 for cardiomyopathy.
- Alnylam is focused on its broader clinical pipeline, including a Phase 1 study for Huntington's disease, which is considered a key program.
- The market for TTR amyloidosis with cardiomyopathy is expected to grow for years, as only 20% of the estimated 150,000 U.S. patients are currently diagnosed.
- Alnylam is on track to achieve its P5x25 goals, including sustainable non-GAAP profitability, and plans to announce new five-year objectives early next year.
Nov 19, 2025, 11:30 AM
Alnylam Pharmaceuticals Reports Strong Q3 2025 CM Revenue and Achieves 2025 Goals
ALNY
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Alnylam Pharmaceuticals reported $300 million in cardiomyopathy (CM) revenue for Q3 2025, doubling Q2 revenue, and upgraded full-year guidance for the TTR business by $275 million at the midpoint.
- The company successfully achieved its "P to the fifth by 25" goals, including a 40% CAGR in top-line growth and reaching non-GAAP profitability.
- New 2030 goals will be unveiled at JPMorgan, focusing on TTR leadership, pipeline progression beyond TTR, and the company's financial profile (top-line and margin).
- The Amvuttra launch for CM is demonstrating strong momentum with rapid formulary access and effective payer policies enabling first-line access, anticipating a mid-single-digit year-over-year price decline for the TTR business in 2025, which is expected to be offset by significant volume growth.
- Alnylam is advancing Zilebesiran, its next-generation product, which is expected to achieve 95% TTR reduction with twice-annual dosing, and has initiated outcome studies for ATTR cardiomyopathy and hereditary polyneuropathy.
Nov 10, 2025, 3:15 PM
Alnylam Pharmaceuticals Reports Strong Q3 CM Revenue and Updates on 2025 Goals and Future Pipeline
ALNY
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Alnylam Pharmaceuticals reported strong Q3 2025 cardiomyopathy (CM) revenue of $300 million and raised full-year guidance for the second time, increasing the midpoint by $275 million for the TTR business.
- The company is on track to achieve its P5x25 goals by the end of 2025, including exceeding a 40% CAGR for top-line growth and reaching non-GAAP profitability. New 2030 goals focusing on TTR leadership, pipeline growth, and financial profile will be unveiled at JPMorgan.
- For its TTR business, Alnylam anticipates a mid-single-digit year-over-year net price decline in 2025, with volume growth expected to offset this reduction, a trend projected to continue into 2026.
- The next-generation product, Zilebesiran, is expected to launch for CM around 2030 (and hereditary PN a year or two earlier), offering an anticipated 95% TTR reduction with twice-annual dosing, and is expected to significantly expand gross margins due to no royalty burden.
Nov 10, 2025, 3:15 PM
Alnylam Pharmaceuticals Reports Strong Q3 CM Revenue and Outlines Future Goals
ALNY
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Alnylam Pharmaceuticals reported $300 million in cardiomyopathy (CM) revenue for Q3 2025, doubling its Q2 revenue, and upgraded its full-year guidance for the TTR business a second time.
- The company has achieved its "P5 by 25" five-year goals, including exceeding a 40% CAGR for top-line growth and reaching non-GAAP profitability.
- Alnylam plans to announce new 2030 goals at JPMorgan, which will likely focus on TTR leadership, pipeline progression beyond TTR, and the company's evolving financial profile, including top-line expectations and margin profile.
- The successful launch of the cardiomyopathy indication was driven by faster-than-anticipated access and first-line positioning for Amvuttra, with a projected mid-single-digit year-over-year price decline for the TTR business in 2025 expected to be offset by significant volume growth.
- The next-generation product, Zilebesiran, is anticipated to launch in CM around 2030 with better efficacy and twice-annual dosing, offering potential for significant margin expansion due to no royalty burden.
Nov 10, 2025, 3:15 PM
Alnylam Reports Strong Q3 2025 Results and Raises Full-Year Guidance
ALNY
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Alnylam reported Q3 2025 revenue of $1.249 billion and net income of $251.1 million, marking a swing to profitability and an adjusted EPS of $2.90, significantly beating the Zacks consensus of $1.67.
- The quarter's performance was primarily driven by Amvuttra sales, which generated approximately $685 million, with ATTR-CM revenues from Amvuttra about doubling from Q2.
- Management raised its 2025 revenue guidance to about $3.05 billion, citing robust Amvuttra launch momentum.
- Despite the positive results and increased guidance, shares fell approximately 7% after the release, following a roughly 105% year-to-date gain.
Oct 30, 2025, 7:40 PM
Alnylam Reports Strong Q3 2025 Results and Raises Full-Year Guidance
ALNY
Earnings
Guidance Update
Product Launch
- Alnylam Pharmaceuticals reported Q3 2025 total net product revenues of $851 million, marking a 103% year-over-year growth. This was driven by TTR franchise revenues of $724 million, up 135% year-over-year, with U.S. TTR revenues reaching $543 million, a 194% year-over-year increase.
- The company increased its total net product revenue guidance for 2025 from a range of $2.65 billion-$2.8 billion to a revised range of $2.95 billion-$3.05 billion, representing a $275 million or 10% increase at the midpoint.
- The AMVUTTRA® ATTR cardiomyopathy launch continued its strong momentum, with patient demand roughly doubling quarter-over-quarter in Q3 2025. Health System Setup for AMVUTTRA® is now complete, and payer coverage remains broad.
- Alnylam advanced its pipeline with the initiation of the ZENITH phase III cardiovascular outcomes trial for zilebesiran and the upcoming initiation of the TRITON-PN study for nucresiran in hATTR-PN.
Oct 30, 2025, 12:30 PM
Quarterly earnings call transcripts for ALNYLAM PHARMACEUTICALS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more